USING DISEASE FREE SURVIVAL (DFS) AS A PRIMARY ENDPOINT IN EARLY BREAST CANCERIDDI in collaboration with Roche have identified why using disease-free survival as a primary endpoint in early breast cancer is the way forward!
BAYESIAN OUTCOME-ADAPTIVE RANDOMIZATION DESIGNS: A PROMISE NOT WITHOUT PERILLearn on the principles of OAR designs – The key considerations for implementing Bayesian OAR designs and potential challenges ahead – The impact of selected elements of OAR designs on operational characteristics of a clinical trial – The advantages and disadvantages of OAR designs.
Elisabeth (Els) Coart, M.Sc, PhD, Director, Consulting Services Els joined IDDI in 2011, initially for research work related to biomarkers in Alzheimer’s disease. She has a strong background in assay development combined with 10 years’ experience as statistician for biotech and diagnostic industries. Over the past several years, Els has gained comprehensive experience in study design for oncology and has become IDDI’s expert in analytical and clinical validation of (companion) diagnostics, or IVDs. She has represented IDDI in symposia, publications, and countless interactions with prospects and clients. Els shares her high level of expertise with our team of consultants and has been instrumental in making this team grow over the last couple of years.
FAST GROWING COMPANY
OPENING OF A SECOND EUROPEAN OFFICEIDDI has opened a new office in Mont-Saint-Guibert, Belgium to accommodate accelerated growth. This new location houses up to 40 additional employees.
MORE THAN 20 NEW EMPLOYEES SINCE BEGINNING OF THE YEARInterested in joining us? View our career page! Tremendous opportunities in Belgium and in the US. Apply today!
